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REVIEW
Dry powder inhalation: past, present and future
A. H. de Boera, P. Hagedoorna, M. Hoppentochta, F. Buttinib, F. Grasmeijera and H. W. Frijlinka
aDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands; bDepartment of Pharmacy,
University of Parma, Parma, Italy
ABSTRACT
Introduction: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD
therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion
principles. Therefore, particle engineering and powder processing are increasingly applied to achieve
acceptable lung deposition with these poorly designed inhalers.
Areas covered: The consequences of the choices made for early DPI development with respect of
efficacy, production costs and safety and the tremendous amount of energy put into understanding
and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed
particle manufacturing and powder formulation processes are presented as well as the challenges,
objectives, and new tools available for future DPI design.
Expert opinion: Improved inhaler design is desired to make DPIs for future applications cost-effective
and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via
the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by
increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and
designing simple and self-intuitive inhalers, which give good feedback to the patient about the
inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations,
disposable inhalers may be preferred.
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The history of inhalation therapy has been described before
[1–4]. It dates back to more than 4000 years ago when in India
powdered Durata stramonium and Durata ferox, containing
potent alkaloids with anticholinergic bronchodilating proper-
ties, were smoked after mixing with other compounds such as
ginger and pepper [1]. Drug inhalation gained interest for the
treatment of respiratory diseases particularly after Philip Stern
acknowledged in 1764, ‘the only possible way of applying
medicines directly to the lung is through the windpipe’ [4].
This resulted in the development of a variety of ceramic
inhalers in the eighteenth century for drawing the inhaled
air through infusions of plants and other ingredients [1]. In
the early 1900s, hand-bulb nebulizers became popular for
supplying adrenaline chloride as bronchodilator, and in the
twentieth century, electric and ultrasonic nebulizers were
developed [1,2]. In 1956, a completely new principle for wet
aerosol generation was introduced: the ‘Metered Dose Inhaler’
(MDI, Riker Laboratories), driven by propellants [2]. The MDI
became rapidly popular because this type of device is small
(portable), inexpensive, theoretically easy to use, fast, and
silent compared to nebulizer equipment. In spite of their
advantages over nebulizers, many patients had difficulties in
operating an MDI correctly. In addition, a great concern about
the future for MDIs was raised on account of the discovery in
the early 1970s that CFC propellants contribute to the deple-
tion of the ozone layer in the stratosphere [5,6]. This discovery
resulted in the Montreal protocol on substances that deplete
the ozone layer, which entered into force in January 1989 to
phase out production of the substances that are responsible
for this depletion [7,8]. The uncertain situation about MDIs
became a major driver for dry powder inhalation, and dry
powder inhalers (DPIs) are currently considered as the type
of pulmonary drug administration device with the greatest
potential for improved and new therapies.
The aim of this review was to evaluate the past, present,
and (expected) future of DPI development. It will be discussed
that a lot of effort is currently put in formulation research to
obtain acceptable performance with poorly designed DPI con-
cepts from the past. For DPI innovation in the future, breaking
with this tradition is necessary. Safer, simpler, cheaper, and yet
more effective DPIs are necessary to make high expectations
about mass vaccination and TB therapy, particularly in devel-
oping countries, come true.
2. Dry powder inhalation: past
DPIs are already known since mid-eighteenth century from
Vincent Alfred Newton’s UK patent 1161 [9]. His device,
meant to deliver pulverized potassium chloride, was never
manufactured on an industrial scale, however. This, in contrast
with the Aerohalor of Abbott, which was launched nearly
100 years later in 1948 and used for the delivery of penicillin
and norethisterone, a bronchodilator [4]. The Aerohalor served
as a prototype for the various capsule inhalers developed in
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the period of 1950–1980. These inhalers contained a lactose-
based drug formulation in small capsules or ‘sifters’. For the
development of the first device marketed in this period, the
Fisons Spinhaler® (1967), the high dose (20 mg of cromogly-
cate sodium, which is too high for MDIs) was the main driver
[4,10]. Bell et al. tested a lactose-based formulation (1:1 with
the drug by weight) for this drug too and concluded that the
emptying efficiency of the capsule depends very much on the
size fraction of the lactose used [11]. Several patents for
different inhaler concepts were filed between 1950 and 1980
e.g. [12–17], but only the inventions that made use of the
same basic design principles reached the market. They all had
gelatin capsules as dose container and a lactose (carrier)-
based formulation for the drug [18]. Differences were primarily
confined to the means for opening or piercing the capsule and
the way in which the capsule is spinning, vibrating, or wob-
bling to release its contents during inhalation. In 1969, the
Rotahaler® was launched (Allen & Hanbury’s) [19], followed by
the Inhalator Ingelheim in the 1980s (Boehringer Ingelheim)
[20] and the Cyclohaler® in the early 1990s (Pharmachemie)
[21]. The latter is also known as the ISF®-inhaler and was
patented in 1974 [14]. The choice for hard gelatin capsules
as dose compartment for the drug seemed obvious, as filling
equipment for this dosage form was available and did not
need to be developed. Drugs against asthma and chronic
obstructive pulmonary disease in the microgram range, for
which the capsule inhalers were developed, have to be
diluted, and their flow properties improved for reproducible
capsule filling. Therefore, using carrier-based formulations for
such low doses was a logical choice too. Jones and Pilpel were
among the first to describe the strong adhesion of micronized
particles to the surfaces of much larger host (carrier) particles
during mixing [22], and this phenomenon was studied more
systematically in 1971 by Shotton and Orr [23] and Travers and
White [24]. It was recognized by Hersey in 1975 that this type
of mixing is basically different from random mixing, and for
that reason, he named it ordered mixing [25]. More than 10
years later and after intensive debate about the nomenclature,
Staniforth (1987) presented very good arguments to replace
the name ‘ordered’ by ‘adhesive’ [26]. In tablet manufacturing
for very potent drugs, the objective was to obtain maximal
mixture homogeneity and stability. First, when the relevance
of adhesive mixtures to inhalation increased, improving dis-
lodgement of the micronized drug particles from the carrier
crystals during inhalation became the main objective (see
paragraph 3.1). After the first capsule-based DPIs, multidose
reservoir inhalers were introduced from the 1990s onwards,
having the same adhesive powder formulations for the drug.
They were designed with various dose measuring principles,
including slides (e.g. Novolizer®, Meda Pharma) [27–29], cylin-
ders (e.g. Easyhaler®, Orion Pharma) [30], and disks (e.g.
Pulvinal®, Chiesi Farmaceutici) [31] with dose cavities, or hol-
low shafts (e.g. Taifun®, Leiras Oy) [32,33], operated by the
patient. Similar multidose DPIs developed in the same period
are the Twisthaler® (Merck,Sharp & Dohme Ltd) [34],
Clickhaler® (Vectura) [35], SkyeHaler® (SkyePharma), marketed
as Certihaler® by Novartis [36], and Airmax® (Norton
Healthcare) [37], the latter currently known as Spiromax®
(TEVA) [38]. Adhesive mixtures were also applied in the first
multiple unit-dose blister inhalers from the 1990s, the
Diskhaler® [39] and Diskus® [40] of Glaxo(Smith Kline). The
only exception to the rule is the Turbuhaler®, introduced by
Astra(Zeneca) in the late 1980s [41]. Micronized drugs for
delivery with this multidose reservoir inhaler are transformed
by spheronization into soft aggregates (originally without
micronized lactose) to obtain a carrier-free formulation.
Nearly all DPIs developed before 2010 were so-called passive,
or breath-actuated devices.
3. Dry powder inhalation: present
New inhaler concept developments may easily stretch over
periods of 10-15 years. What was started several years ago
may not reach the patient in the next half a decade. The
patent literature may tell what is going on but cannot reveal
which developments will be successful; only few of the
patented inventions reach the market. Therefore, the bound-
ary between past and present is blurred, and for the sake of
continuity, the period from approximately 1990 onwards will
be considered (at least partly) as the present. Currently, at
least five mainstream developments can be distinguished
related primarily to dry powder inhalation:
(1) ‘repair actions’ for the design weaknesses of the early
inhaler concepts
(2) formulation of high-dose drugs (‘particle engineering’)
(3) development of inhalers and formulations for vaccines
and systemically acting drugs
(4) understanding (and controlling) pulmonary drug
deposition and distribution from DPIs
(5) miscellaneous innovative developments.
Additionally, one of the main concerns in relation to the use of
these breath actuated DPIs is that patients may not be able to
generate a sufficient flow rate for extracting the dose and
good powder dispersion and hence, achieving the desired
therapeutic effect [42]. This resulted in the development of
active DPIs, like the inhalers of the Spiros® platform (Dura
Pharmaceuticals), which have a battery-operated propeller
[43] and the Exubera® insulin inhaler (Pfizer) which utilizes
Article highlights
● Early dry powder inhalers have a poor drug delivery performance due
to design weaknesses
● Formulation studies currently outnumber device design and devel-
opment studies and are meant to make old inhaler concepts perform
better
● Large amounts of excipients in high dose formulations are unwanted:
they increase the number of inhalations of a single dose, whereas
their safety in the long term is uncertain
● New applications, particularly pulmonary vaccination, require more
effective inhalers
● Future inhalers have to be simple (but effective) and give good
feedback to the patient to increase adherence to the therapy
● Several applications (e.g. delivery of hygroscopic drug formulations
and vaccination) are served better with disposable inhalers
This box summarizes key points contained in the article.
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pressurized air from a hand piston for active powder disper-
sion [44]. Such inhalers basically deliver a patient (i.e. flow
rate) independent fine particle aerosol [45], which has long
been considered an advantage [46,47]. An increasing delivered
fine particle dose with increasing flow rate can compensate for
the increased oropharyngeal losses, however, thus yielding a
more constant lung deposition and higher distribution unifor-
mity [29,48–50]. Besides, both active inhalers were not suc-
cessfully marketed. They were complex and, therefore,
expensive, vulnerable to failure in case of flat batteries
(Spiros), and user-unfriendly because of the large number of
operational steps and the large size of the apparatus
(Exubera). For these reasons, active DPIs will not further be
discussed in this review.
Finally, the therapeutic and commercial success of combination
products results in one of the most noticeable therapy changes of
the present [51]. This also concerns dry powder inhalation.
3.1. ‘Repair actions’ for design weaknesses of early DPI
concepts
The initiative to develop DPIs may have been the result of
some well-defined needs [18,42,52–54]; the choices made for
their design indicate that the development itself was driven by
existing expertise. The availability of capsule filling equipment
and the emerging expertise in dry powder formulation of
potent drugs enabled to keep DPI development cheap and
simple and made DPIs cost compatible with MDIs. However,
currently, these choices can be considered the DPI design
weaknesses. Both in vitro and in vivo deposition studies
show that delivered drug fractions in the required aerody-
namic size fraction from early capsule-based DPIs with adhe-
sive mixtures are quite low (Figure 1) [55,56]. The carrier-free
formulation from the Turbuhaler generally performs much
better, even in comparison with MDIs that deliver the same
drug [57,58]. The explanation for this poor performance of the
early capsule-based DPIs is in the strong interparticulate forces
in the adhesive mixtures and the absence of efficient disper-
sion principles in these inhalers. To have some dispersion of
the formulation at all, the inhaler resistance is kept low to
enable high flow rates for sufficient dispersion energy [59].
This has the consequence of high mouth–throat depositions
[60,61]. As a response to the inefficient dispersion of adhesive
mixtures, an abundance of studies into understanding and
controlling the variables and mechanisms involved in the
drug–drug and drug–carrier interaction (and dispersion) was
started. Many of these studies have recently been reviewed
[62,63], and most of them focus on selecting the most appro-
priate carrier size fraction [64,65], controlling or modifying the
carrier (surface) morphology [66–68], and varying the amount
of (drug and/or excipient) fines in the mixture [69,70].
Additionally, the effects of carrier shape, grade, and type and
the influence of the mixing conditions on the dispersibility of
the inhalation powders have been studied intensively [63]. An
interesting theoretical approach for a better understanding of
the performance of carrier-based formulations is also the
cohesion–adhesion balance [71]. According to this approach,
drug particles exhibit a preference for attachment to each
other, resulting in drug particle agglomeration, or to the
carrier surface, depending on the balance between cohesive-
ness to adhesiveness of the particles present in the mixture.
When the ratio of cohesion to adhesion is >1, a tendency for
drug particle agglomeration during blending exists, which
promotes dispersion during inhalation. None of the aforemen-
tioned studies has really resulted in significant improvement
so far, however. Complicating factors are not only the many
variables involved, but in particular, also the interactions
between these variables. Mostly, only one or two of these
variables are controlled and studied for their effect, but
when (some of) the other variables are chosen differently
between studies, comparison of data is difficult, and see-
mingly contradicting results may be obtained [62,63].
Therefore, alternative approaches have been introduced. As
has been mentioned already, the use of a lactose carrier has
been avoided for the formulations in the Turbuhaler [41]. An
alternative way to refrain from the use of a particulate carrier
is to store the drug on a microstructured carrier tape [72]. This
Taper DPI (3M™) is another example of an active inhaler
releasing the dose by vibration of the tape [73]. Jethaler®
(Ratiopharm) and MAGhaler® (Mundipharma) are DPIs with
the carrier-based drug formulation compacted by isostatic
pressure technique into a ring-shaped tablet [74]. Measuring
a dose is performed by scraping an amount of powder from
the ring, and the high mechanical forces also overcome part of
the interparticulate forces between the carrier and the drug
[75]. In addition to controlling the carrier (surface) morphol-
ogy, also drug particle engineering processes have been
applied. Examples are co-crystallization of drugs and excipi-
ents by standard spray drying [76], spray drying using super-
critical enhanced atomization [77], or supercritical fluids
crystallization (SEDs: solution-enhanced dispersion by super-
critical fluids) [72,78]. Such particles generally exhibit
improved dispersion performance [79,80]. Another approach
Figure 1. In vitro delivered fine particle doses as percent of label claim (FPFs <
5 µm) from various DPIs tested at 4 kPa (high resistance devices) or 2 kPa (low
resistance devices): range of flow rates 40–75 L/min using a Next Generation
Impactor. Data derived from different comparative in vitro evaluation studies
performed by the authors at the same conditions for direct comparision. Grey
bars are for inhalers carrying adhesive mixtures; dark grey bars with force
control agents in the formulation. Shaded bars are for carrier free (Turbuhaler)
formulations. FPFs are for budesonide (Easyhaler, Cyclohaler, M2 and M3
Turbuhaler and Novolizer), fluticason propionate (Diskus and Elpenhaler), beclo-
metason dipropionate (NEXThaler), aclidinium bromide (Genuair), tiotropium
bromide (Handihaler), indacaterol maleate (Breezhaler) and disodium cromogly-
cate (Spinhaler).
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to obtain better dispersion performance of adhesive mixtures
finds its origin in the work of Staniforth [81]. He used small
amounts (not more than 0.1–5%) of antiadherent or antifric-
tion additive in carrier-based mixtures to reduce the adhesive
force between the carrier and active particles. This concept
has been elaborated into the PowderHale® technology by the
University of Bath and Vectura, using magnesium stearate or
leucine as additives, later referred to as Force Control Agents
(FCAs). The technology, based on a dry mechanical fusion
(mechanofusion) process [82,83], is licensed by Vectura to
GlaxoSmithKline (for the formulations in the Ellipta®) [84]
and Novartis (for the Breezhaler®) [85]. Also the Chiesi powder
formulation for beclomethasone dipropionate and formoterol
fumarate (Foster, or Fostair), administered with the
NEXThaler® device, contains magnesium stearate. Chiesi was
granted their own proprietary technology on the use of mag-
nesium stearate on the basis of improved dispersion as well as
improved resistance to moisture which leads to a higher
physical and chemical stability of the powder mixture [86,87].
All previously mentioned (drug and carrier) particle mod-
ifying and engineering techniques and the addition of FCAs
are meant to decrease the high interparticulate forces in
adhesive mixtures for inhalation. This is needed because of
the absence of efficient dispersion principles in most early
inhaler concepts, and these developments may, therefore, be
considered ‘repair actions’ for poor inhaler device design. The
NEXThaler device also delivers a so-called ‘extrafine beclo-
methasone and formoterol aerosol’ with particles micronized
to a mass median aerodynamic diameter (MMAD) <1.5 μm.
Chiesi claims to achieve higher lung deposition with better
penetration into the small airways with such particles, com-
pared to inhalation powders with a larger MMAD, due to lower
oropharyngeal losses [88,89]. The magnesium stearate in the
formulation facilitates effective dispersion of such small drug
particles. The delivery of such extrafine aerosols is in essence
to compensate for the high flow rate from (most) early DPIs.
All these repair actions for the weaknesses of early DPI design
make the drug formulations complex, more expensive, and
less safe due to the use of excipients. This could have been
avoided by designing more effective inhaler devices instead. It
should, therefore, be recommended that in the future, more
energy is put in designing better devices as part of formula-
tion-device integrated developments.
3.2. Formulation of high-dose drugs
The problems encountered with high-dose drug formulations for
inhalation are essentially the same as those with adhesive mix-
tures, because they are tested and administered with the same
capsule-based inhalers such as Spinhaler, Aerolizer®, Eclipse®, and
Turbospin® [90–95]. The interparticulate cohesive forces are too
high, which makes high flow rates necessary for acceptable dis-
persion, whereas capsule emptying can be problematic too. It
may, therefore, not be surprising that at least partly the same
powder processing and particle engineering techniques as used
for low doses are also applied for dispersion improvement of high-
dose drug formulations. Improvement can often be obtained by
preparing low-density (high-porosity) particles. Different methods
can be applied to decrease particle density, such as creating
hollow particles (void space on the inside), particles with corru-
gated or wrinkled surfaces (void space on the outside), or solid
foam particles. The conditions to obtain such particles by spray
drying and the excipients needed have been explained in an
excellent review by Vehring [96]. Such particles decrease the
powder bulk density (i.e. the number of contact points per parti-
cle) and also have a smaller surface area per contact point, which
decreases the number and magnitude of the interparticulate
forces in the powder. One of the most successful technologies in
this respect is PulmoSphere™ (Novartis, developed by Nektar
Therapeutics) [95]. Particle engineering is also needed to achieve
stabilization of large molecules (biopharmaceuticals) in the dry
state with sugar glasses (cryoprotectants) [97–101], prolonged
drug release or therapeutic effect (e.g. by mucoadhesion) [102–
107], and enhanced drug absorption [106,108]. Particle processing
can furthermore be used to prevent or retard moisture uptake by
hygroscopic drugs [94,109,110], to escape macrophage clearance
[111], or, in contrast, to target specifically the alveolar macro-
phages [112,113], even though the conditions that influence par-
ticle uptake by macrophages are still widely unknown [114]. Also,
particle coprocessing with hygroscopic excipients, such as sodium
chloride and mannitol, to achieve excipient enhanced particle
growth may be desired for enhanced deposition in the deep
lung [115,116]. Moisture absorption by such particles during trans-
port through the airways results in a higher particle mass, and this
increases the sedimentation velocity. The plethora of publications
regarding these particle processing techniques for inhalation pow-
ders makes it virtually impossible to provide a complete survey,
but interesting reviews on formulation strategy and excipient use
for (high dose) inhalation powders were recently written by Pilcer
and Amighi [117] and Hoppentocht et al. [118,119].
When previously mentioned effects such as drug stabilization,
macrophage targeting, or sustained release are not needed, how-
ever, and particle engineering is applied for dispersion improve-
ment only, its use should be critically evaluated for high-dose
drugs. Such powders are frequently highly voluminous because
of their extreme porosity, particularly when being prepared by
freeze drying [120], spray-freeze drying [98,121], or spray drying
with volatile or blowing agents [94,122]. The excipients used
furthermore increase the dose weight to be administered, and
for high-dose drugs, this may also increase the number of inhala-
tions per dose. In some studies, the drug-loaded particles contain
only a few percent of the active, which, for the example of inhaled
antibiotics, canbring the inhaledpowder dose into thegram range
[107]. Many particle engineering processes also require multiple
unit operations, which makes such powders expensive and
increases the risk of batch variation. Finally, a variety of excipients
are used of which somemay pose an immediate risk to the patient
or be harmful in the long term.Only safe excipients should be used
in the smallest possible amounts in high-dose drug formulations;
even small fractions of an excipient in a high-dose drug formula-
tionmay still be administered in significant amounts. Alternatively,
dispersion performance improvement can also be achieved with
improved inhaler design. For example, recently, it has been shown
that the use of excipientsmay not even be needed for problematic
drugs such as amikacin in capsule-based inhalers when the spray
drying conditions are optimized to the product [123].
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3.3. DPI design and pulmonary drug deposition and
distribution
A consistent lung dose is considered a prerequisite for an
adequate and efficient therapy. The efficiency (and safety) of
pulmonary drug administration depends on the aerosol prop-
erties and the way in which the aerosol is delivered to the
respiratory tract. The drug formulation and administration
device plays crucial but different roles in this. The formulation
has to contain the drug particles in the desired aerodynamic
size distribution for deposition in the target area. Formulation
design may be needed to achieve previously mentioned
effects [97–116] or a better product stability. DPI devices
need to disperse the formulation effectively into this size
distribution, preferably at the lowest possible flow rate within
the first 0.5 L (children) or 1 L (adults) of inhaled air to achieve
drug distribution over the entire lung. Fine-tuning of the
primary particle size distribution and the inhalation maneuver
enables to target different sites of action with such an inhaler.
Similar to other pulmonary administration devices, the lung
dose from a DPI is considerably lower than the label claim. This is
due to inhaler losses and substantial deposition in the mouth–
throat region (oropharynx), which often amounts to more than
50% of the delivered dose (Figure 2) [49,50,55,56,61]. Figure 2
does not show the extreme variation in oropharyngeal losses
between different inhalers, however, which is strongly influ-
enced by the inhaler resistance. Oropharyngeal losses also vary
with the inhalation maneuver through the same inhaler. The
variability and uncertainty of lung deposition are mostly the
result of variations in extrathoracic deposition, and it has been
hypothesized that throat deposition is the major determinant for
lung deposition of inhaled aerosols [124]. It may be clear that
what is ‘lost’ in the mouth–throat region does not contribute to
the therapeutic effect and can cause adverse local (or systemic)
side effects. Hence, understanding and reducing mouth–throat
deposition are of utmost importance for DPI design.
For the experimental assessment of drug deposition in the
human throat, different anatomical models are used [125–127] to
replace the standard USP induction port for more realistic
deposition. Using such a throat, DeHaan and Finlay obtained a
sigmoidal (averaged) relationship between extrathoracic (mono-
disperse) aerosol deposition (from different devices) and the loga-
rithm of an impaction parameter (IP), showing that mouth–throat
deposition can approach 100% at high IP values [128]. The two
DPIs in their study showed substantially higher deposition than the
nebulizers and an MDI (with holding chamber). In a follow-up
study, they presented the rather extreme differences in oral cavity
deposition for monodisperse aerosol particles (at the same flow
rate) between different DPI designs [61]. They concluded that the
influence of turbulence on oral deposition is relatively small and
that inertial impaction is themajor, but not the unique, deposition
mechanism in the oral cavity. In a study with an idealized pediatric
throat model, the difference in oropharyngeal deposition from
different DPIswas confirmed, but the difference between idealized
adult and pediatric models was almost negligible [129]. Studies
such as these show that DPI design is a major determinant, not
only for the properties of the delivered aerosol but also particularly
for the ‘losses’ in between themouthpiece exit and the target area
below the trachea. Even for particles with the same aerodynamic
diameter released at the same flow rate, differences in extrathor-
acic depositionmay be rather extreme fromdifferent DPI concepts
[61]. For these reasons, DPI device design should focus on mini-
mizing the extrathoracic losses as well as on reducing the patient
variability in the inhalation maneuver. The first is a function of the
DPI’s mouthpiece design rather than that of total device design,
whereas the latter is served best with a medium to high air flow
resistance and an increasing fine particle dosewith increasing flow
rate to compensate for the higher oropharyngeal losses.
Assessing lung deposition and distribution of the aerosol
fraction passing the oropharyngeal region is more challenging
than measuring oropharyngeal deposition. Lung deposition
has to be known for dose finding, fine-tuning of the particle
size distribution of the aerosol, and optimizing the inhalation
maneuver for the inhaler used. In contrast with the mouth–
throat region, in vitro replicas of the entire bronchial tree do
not exist. Therefore, lung deposition assessment relies on
other methods such as deposition modeling, pharmacokinetic
method, and scintigraphy. Particle deposition modeling in the
Figure 2. Fine particle fraction of the delivered dose and part of the delivered dose deposited in the mouth and oropharynx from DPIs carrying adhesive mixtures as
drug formulation. A: current situation. The fraction not released from carrier and the fine particle fraction were averaged for the DPIs presented in Figure 1 and the
oropharyngeal losses were estimated from in vivo deposition studies with radiolabel drugs in various marketed DPIs. B: desired situation to be obtained by improved
dispersion (from 35% to 65% drug detachment) at a lower flow rate (from ≫ 60 L/min to < 40 L/min).
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respiratory tract is based on impaction and sedimentation
probability equations for single particles. They are derived
for simplified situations [130] and make use of standardized
lung models, for instance, as defined by Findeisen or Weibel
[131]. Although such computations teach about the effects of
particle size and velocity on drug deposition in the lungs, they
bear a significant degree of uncertainty for drug deposition in
patients, as diseased lungs may deviate considerably from the
standardized models (and conditions) used for the computa-
tions. For lung deposition studies, radiolabeling techniques
have greater value than PK methods, although both have
been used successfully to estimate total lung dose [132]. PK
data do not allow estimating regional deposition, and the
absorbed dose may be underestimated when the drug is
metabolized. Pharmacokinetic evaluations are also hindered
by a lack of understanding of the relation between deposition
and absorption. For example, a high plasma peak concentra-
tion (Cmax) may be the result of either a high drug concentra-
tion in the upper airways or that of a more even drug
distribution with lower concentrations over the central and
lower airways. The first situation yields a high driving force for
absorption, whereas the second provides a large area for
absorption (low resistance). Even more important is the rather
extreme intersubject variability in absorption of the drug, as
has been found for instance in different studies with tobramy-
cin in different patient groups [95,133,134]. Therefore, PK data
may lead to false conclusions about the real dose deposited.
Radiolabeling techniques for inhaled aerosols from MDIs were
first presented in the 1980s using two-dimensional gamma
cameras [135]. They yielded limited information due to an
overlay of the structures of interest [136]. Three-dimensional
techniques such as single photon emission computed tomo-
graphy and positron emission tomography (PET) provide more
detailed data, although particularly PET poses greater logisti-
cal and technical difficulties [136–138]. Also, the lack of stan-
dardization and the differences in procedures between
different centers have been a concern, as they make compar-
ison of data complex and limit acceptance by the regulatory
authorities [137,139–141]. As a response to that, the
Regulatory Affairs Networking Group of the International
Society for Aerosols in Medicine (ISAM) presented practical
guidance to the methods and techniques for standardizing
radiolabel validation, image acquisition, and analysis [142].
Recent developments are to coimage anatomical structures
from high-resolution computer tomography (CT) scans with
deposition data from radiolabeling technique [137,143]. CT
scans at functional residual capacity and total lung capacity
are also used as boundary conditions for computational fluid
dynamics (CFD) simulation to predict flow behavior and drug
deposition [144]. It is anticipated that this functional respira-
tory imaging may become a tool for personalized respiratory
treatment [145].
3.4. Development of inhalers and formulations for
vaccines and systemically acting drugs
As early as 1958, the feasibility of pulmonary vaccination was
presumed when the inhalation of very small numbers of living
attenuated Mycobacterium tuberculosis by guinea pigs resulted in
development of acquired resistance against airborne infection
with virulent bacilli [146]. Today, pulmonary vaccination is still
in its infancy, and of all possible applications for pulmonary drug
delivery, DPI development for vaccination is probably the most
challenging. Pulmonary vaccination differs at least in two distinct
ways from the administration of most locally and systematically
acting drugs: the delivery is one–off (with at most one or two
booster doses after considerable time), and there is no immedi-
ate measurable therapeutic response. This implies that (nearly) all
vaccinees are inhalation naive, and there is no check on whether
the vaccine administration was successful or not. This poses high
demands on the delivery system for pulmonary vaccines. DPIs
offer the advantage over wet nebulization systems (or MDIs) that
the vaccine is administered in the dry state. Therefore, stability is
less of an issue, and reconstitution from powdered material is not
necessary. But the administration is in one single inhalation act.
This requires that the inhaler performs well and consistent over a
wide range of flow rates and that operating the inhaler correctly
must be intuitive. In addition, practicing of the inhalation man-
euver under supervision of a health-care expert with an empty,
instrumented inhaler must be recommended, and correct vac-
cine delivery must be verified with a feedback system showing
the relevant inspiratory parameters. Recently, the (pre-)clinical
pulmonary vaccine studies were reviewed in which it was
shown that inducing an immune response is possible indeed
[147,148]. However, not all pulmonary vaccines produced and
tested were equally effective in these studies, and this could be
due to differences in the formulation properties (particularly the
aerodynamic size distribution of the delivered aerosols) and
delivery efficiencies from different inhalation devices. More
research into the desired site of deposition, the intrinsic immu-
nogenicity of the antigen to activate the innate immune system,
and the choice of adjuvants is necessary. Special attention has to
be given also to DPI development for school children, after
infants and toddlers probably the most relevant age group for
pulmonary vaccination. For children, not only respiratory but also
cognitive skills may be limiting factors for correct DPI use [149]. It
has recently been shown that most children from 5 years on can
understand and comply well with the inhalation instruction
given [150]. However, inhaled volumes and flow rates were low
and require that the majority of the dose is delivered within 0.5 L
of inhaled air and that dispersion of the powder formulation is
good at a peak flow (PIF) of only 25–40 L/min [150]. Obviously,
inhaled volume and PIF depended on the DPI resistance, but the
minimal values (0.5 L and 25 L/min) obtained in the study did
not vary so much between the different age groups for the
highest airflow resistance. More worrying is the observation in
this study that a high incidence of narrowing of the passageway
for the aerosol (by teeth, tongue, or cheeks) was observed in
90% of the inhalations, depending on the DPI mouthpiece
design (Figure 3). Also, exhalation through the DPI prior to
inhalation occurred. This may require special features for a pedia-
tric DPI.
DPIs for systemic drug delivery are not fundamentally dif-
ferent from devices for local therapies in the lungs. Inhalation
seems attractive as noninvasive route for the delivery of pep-
tides and proteins that otherwise must be injected, because
the respiratory tract offers an enormous absorptive surface
area for drug absorption [151,152]. It has long been believed
504 A. H. DE BOER ET AL.
that deposition in the most distal airways is needed for a high
and reliable bioavailability. This would require an appropriate
particle size distribution (approx. 1–3 μm), deep inhalation of
the aerosol at a low flow rate (after previous exhalation to
residual volume), and a long breath hold time. And even then,
drug deposition on all different epithelial surfaces is inevitable.
However, it is now recognized that the preferred site of
deposition may depend on the type of drug, e.g. certain
antibodies are preferentially absorbed in the upper air-
ways [152].
3.5. Miscellaneous innovative developments
The profusion of developments and the diversity of applica-
tions for pulmonary drug delivery (as dry powder) make it
impossible to give a complete survey. A fair conclusion is
that formulation developments outnumber the device devel-
opments. Many trends in powder formulation have already
been mentioned in the paragraphs 3.1 and 3.2. Relatively
new is the interest in nanoparticulate systems for inhalation
[153,154], and an abundance of articles on this subject has
been published particularly since 2005. The application of
nanosystems has been investigated for drug, protein, and
gene delivery through the respiratory tract because of their
ability to escape (alveolar) macrophages and mucociliary clear-
ance mechanisms [154]. This prolongs their residence time.
They can also enter intercellular compartments to increase
bioavailability but exhibit poor lung deposition efficiency
and high formulation instability. Another method proposed
for evading macrophage uptake in the deep lung is by making
liposomal particles, using phospholipids similar to endogen-
ous lung surfactant. Such particles are less foreign to alveolar
macrophages [155]. Liposomal formulations are also used for
controlled drug release and enhanced formulation stability,
but scaling-up the manufacturing process to an industrial
scale is often problematic. Highly innovative is the principle
of micromolding particles with defined uniform shape, size,
and morphology, termed PRINT® (Liquidia) [156]. The techni-
que is compatible with biopharmaceuticals such as proteins
and oligonucleotides and yields particles in a size range sui-
table for inhalation. In the field of DPI development, the need
for high-dose delivery devices becomes urgent, particularly for
the delivery of antibiotics in cystic fibrosis (CF), TB, and other
infectious lung diseases. Noticeable in this respect is that all
known device developments are from academia, such as the
Twincer™ [157], the Cyclops [158], and the Orbital® multi-
breath DPI [159,160]. Also, a new high-dose DPI based on
fluidized bed design is developed in the academic setting
[161]. The industry, in contrast, has chosen for existing capsule
inhalers for dry powder tobramycin (Novartis, TOBI®), cipro-
floxacin (Bayer Pharma AG), colistin sulfomethate (Forest
Laboratories, Colobreathe®), and mannitol (Pharmaxis,
Aridol®) using the Turbospin (named Podhaler® for TOBI)
and RS01 (for Aridol), a high-resistance version of the ISF
inhaler, respectively. All these devices have a prefabricated
powder formulation in common. A completely different
approach is the Staccato® system of Alexza Pharmaceuticals.
The basic concept of this system is rapid and efficient vapor-
ization of a thin film of pure drug coated on a metallic sub-
strate inside a passageway for the inhaled air [162]. Heating to
400°C for evaporation of the drug in approx. 0.2 s is triggered
by the inhaled air stream and followed by condensation to
produce the inhaled aerosol particles before the drug is
inhaled. The system is developed for loxapine. Innovative are
also the Technosphere® technology of MannKind and the
iSPERSE™ platform of Pulmatrix. The Technosphere® technol-
ogy makes use of self-assembling (fumaryl diketopiperazine,
FDKP) carrier particles with a high surface area for absorption
of large active molecules [163]. The carrier particles are in the
micron size range and small enough to be inhaled. This has
the advantage that drug and carrier need not to be separated
before inhalation. The principle has been used to develop
Technosphere Insulin (AFREZZA®) which is inhaled with a
new DreamBoat™ inhaler [164]. iSPERSE™ powders consist of
dense salt-containing particles in an appropriate size range for
inhalation. They are highly dispersible without blending with
lactose and contain typically less than 20% excipients in for-
mulations with the drug, or drug combination. iSPERSE™
Figure 3. The oral cavity during DPI use of a child. a: Captures from a video recording of the changes in the passageway for the aerosol during a single inhalation
manoeuvre; b; examples of a narrowed passageway by elevated tongue and inwards directed displacement of the cheeks (captures from different video recordings
of different children showing some extreme situations). The recordings were made using a bronchoscope in the mouthpiece of a test inhaler with exchangeable
mouthpieces and air flow resistances [150].
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particles enable processing of both large-molecule and low-
potency drugs [165].
On the application site, new dry powder bronchial chal-
lenge tests have recently been presented for methacholine
and adenosine [110,166] in addition to the mannitol test [167].
4. Dry powder inhalation: future
In 1995, it was written: ‘it is possibly the “power assisted”
multidose dry powder inhalers which represent the real “new
wave” of powder aerosol delivery’ [18]. Today, 20 years later,
no active DPI has been successful on the market yet. In the
early 1990s, also the first manuscripts about the promising
perspectives of aerosolized medication for gene and peptide
therapy were published [168]. It was anticipated that ‘in the
near future, optimal formulations will be combined with mod-
ified aerosol delivery devices to achieve reproducible dosing’.
Again 20 years later, it has to be acknowledged that still more
efficient aerosol devices are needed, that formulations have to
be safer and bioavailability has to be improved [169]. McElroy
et al. compared the results for inhaled proteins from different
studies, showing that systemic bioavailability for compounds
with mol weights (MWs) <10 kDa can vary from almost 0% to
100%, whereas for MWs >10 kDa, 60% is maximal (so far) [170].
Therefore, bioavailabilities are often too low for cost-effective
and reliable treatments [152]. Besides, pulmonary administra-
tion of one of the most interesting candidates at the time,
insulin, may be less relevant today because of the refinement
of subcutaneous injection devices and new pharmacological
strategies for patients with type 2 diabetes [171]. These exam-
ples show how difficult it is to predict the future of DPI
therapy. Many large biopharmaceuticals may eventually
appear to be unsuitable for inhalation. Smaller molecules, on
the other hand, such as levodopa, loxapine, and (locally act-
ing) iloprost or sildenafil (MWs ≪1 kDa) seem to have con-
siderably greater future perspective. Currently, the treatment
of infectious lung diseases with inhaled antibiotics is in the
spotlight. An advantage is the deposition directly at the site of
infection, which makes higher local concentrations, and thus, a
more effective therapy possible without increasing the
adverse systemic effects. Higher concentrations also could
make drug-resistant organisms susceptible to the antibacterial
drugs again. Some inhaled dry powder antibiotics are on the
market already (e.g. TOBI from Novartis and Colobreathe from
Forest Laboratories for CF therapy) or are expected to obtain
approval soon (Ciprofloxacin DPI from Bayer HealthCare for
bronchiectasis therapy). For all these drugs, classic capsule
inhalers are used. Therapy for diseases such as TB is much
more challenging because of the higher doses involved. For
the future, the success of pulmonary TB treatment may
depend on the development of efficient novel high-dose
DPIs and synergistic drug combinations to minimize the num-
ber of inhalations. Some studies with proven synergistic effect
of antibiotic combinations have recently already been
reviewed e.g. [118]. Particularly for inhaled antibiotics, the
need for good patient compliance with the instructions, mini-
mizing patient errors, and good adherence to the therapy are
prerequisites for an effective treatment. Also, the expectations
for dry powder pulmonary vaccination are currently high. The
advantages are improved stability (in the dry state), no recon-
stitution needed (requiring sterile water), and noninvasive
administration (no needle technology) [148]. However, inhaled
vaccination as one-off administration depends on a high relia-
bility regarding delivered fine particle dose on the target area.
This requires highly efficient inhaler technology which also
needs to be disposable, simple, and cheap to facilitate mass
vaccination programs in developing countries [172]. It may
also be of utmost importance to develop reusable instruction
and feedback systems for such disposable inhalers in order to
practice the inhalation maneuver and check correct inhalation
during vaccine delivery. Disposable DPIs are furthermore
recommended for hygroscopic drug formulations and antibio-
tics [172]. For a realistic future expectation, it may be wise not
to think too much in terms of feasible applications, however,
but rather in terms of DPI technique itself and what is possible
with this technique. Future developments will make use of
new tools. New DPI design and development will benefit from
computer-aided design. CFD and discrete element method
may assist optimizing the flow field and particle behavior
inside, but also ex-mouthpiece of the inhaler into the oral
cavity [173–177]. New 3D printing techniques facilitate rapid
DPI prototyping and making casts of (upper) parts the respira-
tory tract based on high-resolution CT scans [178]. Coimaging
may enable to draw better conclusions about respiratory tract
deposition in individual patients with diseased lungs and
eventually facilitate personalized treatment with highly expen-
sive drugs [143–145]. But most important of all may be redu-
cing the cost of inhaled therapy considering the pressure on
health budgets and the rapidly growing demand for inhaled
therapies in developing and newly industrialized countries.
Some of the challenges and objectives for future DPI design
and development are listed in Table 1.
5. Expert opinion
Many reviews on dry powder inhalation have been published
since 1985, but clear visions or strategies for improved DPI
design and future DPI development were scarcely presented.
Most reviews are confined to a state-of-the-art description
with in vitro and in vivo performance data e.g. [179,180] or
performance data in combination with functionality and pro-
duction considerations [181]. Also, new tools and techniques
for DPI device and formulation design have been reviewed
[182], and a few have provided characteristics of an ideal DPI
[183] without presenting a strategy for achieving these char-
acteristics. Many reviews do have the same key design factors
in common, however, such as simplicity, cost-effectiveness,
safety, and flow rate-independent lung deposition. Also, the
needs for reduction of patient errors and device-formulation
integrated development are frequently mentioned. How dif-
ferent is daily practice. The many generic devices on the
market increase the number of different inhalers used by the
same patient, and it is known that this contributes to the
number of patient errors [184]. Future improvement of the
inhalation therapy is, therefore, primarily served by reducing
the number of different inhalers used by the same patient for
the same therapy. However, in practice, several plastic manu-
facturers and consultant agencies continue to develop new
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DPIs without knowing what type of drug or drug formulation
they can or will be used for. This frequently entails a need for
unnecessary powder processing or particle engineering to
obtain an acceptable performance of the combination. This
makes development and production of such inhalers more
expensive and, thus, less cost-effective and also less safe. It
also often requires the use of excipients of which we assume
that they are safe because they are endogenous, or because
we cannot imagine (yet) how they can interact with the phy-
siological processes in the lungs. It should be considered that
the fact that the excipients are endogenous does not make
them safe by definition, however. Their functionality in the
human body does not depend on their presence but on their
concentration and location. Any deviation from the normal
physiological concentration can potentially be harmful. For
instance, sodium chloride and cholesterol are endogenous,
and an occasional high oral intake may not immediately
cause safety problems, but on the long term, they can become
a serious health risk. For cholesterol, it took more than
40 years to acknowledge this after a link between cholesterol
and vascular damage in rabbits was already discovered in the
early 1900s. Obviously, the health risk of exogenous excipi-
ents, such as poly-lactic acid (PLA), chitosan, carrageenan,
hydroxypropyl methylcellulose, magnesium stearate, etc., in
inhalation products is much greater. Parlati et al. recently
prepared drug solutions with sodium stearate for spray drying
and observed micelle formation when this adjuvant was
added in amounts >1% [185]. It can be computed for spray
aerosols in the size range needed for inhalation powders that
amounts slightly over 1% indeed exceed the critical micelle
concentration (CMC) for this salt, and examples such as these
show what might happen locally in the lungs for magnesium
stearate (and other exogenous surfactants) too when they
exceed their CMC. The risks of such nanoparticulate micelles
are still widely unknown. Only for achieving special effects,
such as product stabilization, improved absorption, sustained
action, or macrophage targeting, the use of excipients should
be considered, but their selection and application have to be
weighed carefully against the achieved therapeutic improve-
ment from their use. A logical consequence of refraining from
the use of excipients is that the inhaler design must be
adapted to the physicochemical properties of the drug
(class) [118]. Only device-formulation integrated development
can prevent unnecessary use of excipients and powder for-
mulation and knowing what the inhaler will be used for is a
prerequisite for a good device design. Practically, device-for-
mulation integrated development for the different drugs
needed by the same patient may be a difficult problem to
solve because different manufacturers, having their own stra-
tegies and inhalers, may produce the drugs. They most likely
use different inhalers for that. Generic companies could bring
the solution by making it their strategy to develop the com-
plete range of inhaled medicines for a particular disease in the
same inhaler.
Innovation starts with a better understanding of how lung
deposition can be influenced and controlled and which inhaler
characteristics are most critical in that respect. One of the
most persistent misconceptions in inhalation therapy with
DPIs is the belief that a constant lung deposition depends
on a flow rate-independent fine particle dose [75,76,185]. As
mentioned earlier, a flow rate-independent lung deposition is
served best with a higher fine particle dose at a higher flow
rate to compensate for a higher oropharyngeal deposition.
Additionally, a low flow rate limits the oropharyngeal deposi-
tion, and this requires a medium-high to high inhaler resis-
tance. Innovation also requires breaking with the tradition of
making complex formulations for poorly designed DPIs. More
effective inhalers are needed that are less dependent of the
interparticulate forces in the drug formulation and generate
high fine particle doses at low flow rates without needing
excipient containing particle engineered powders. Achieving
a proper balance between the interparticulate forces in the
mixture, the dispersion forces generated by the inhaler and
the (inertial) deposition forces during inhalation can be the
solution (Figure 4) [118]. Inhalers such as the Novolizer and
Genuair® with air classifier technology as dispersion principle
clearly show that this is very well possible (Figure 1). They
generate high inertial dispersion forces at a medium resistance
(limited flow rate), which makes these inhalers largely inde-
pendent of the interparticulate forces in the formulation. Such
effective inhalers also deliver the desired increasing fine par-
ticle dose with increasing flow rate.
For future DPI developments also the use of hard gelatin or
hydroxypropyl methylcellulose capsules should be reconsid-
ered. Capsules require a threshold value for the flow rate to
achieve adequate emptying by rotation, spinning, or vibration
during inhalation. The high risk of fractioning during piercing
requires that the inhaler is designed with an appropriate screen
in between the capsule chamber and the mouthpiece to pre-
vent that large capsule fragments are inhaled. Capsules also
provide poor moisture protection and need appropriate blister
Table 1. Future challenges and objectives for DPIs.
Challenge/objective Solution
Reducing patient errors – Simple, self-intuitive DPI design
– Minimal number of handling steps
– The same inhaler for all inhaled
medication
Improving patient compliance
with the inhalation instruction
– Simple, self-intuitive DPI design
– Feedback on inhalation performance
Improving patient adherence to
the therapy
– Minimizing the number of inhalations
per dose
– Simple, compact DPI design
– Minimal number of handling steps
Improving safety – No unnecessary excipients




– antibiotics (when there is the risk of
bacterial resistance development in
the DPI)
Improving efficacy – More powerful inhaler design
(balancing between interparticulate,
dispersion, and deposition forces)
Specialized inhalation – Patient (group) tailored DPI design
Reducing the costs of inhaled
therapy
– Simple and cheap (but effective) DPI
design
– Simple drug formulation technologies
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packaging to guarantee long-term stability of moisture-sensitive
drugs and drug formulations. Moreover, the possibility must be
excluded that capsules for inhalation are mistaken for oral cap-
sules or that oral capsules are inhaled. For future applications
(e.g. hygroscopic formulations), it also has to be considered
whether disposable or reusable inhalers are the best option
[172]. Finally, new inhaler technology should enable training of
the proper inhalation technique by providing feedback about
the inhalation maneuver during drug administration to the
patient or the health-care professional during inhalation [186].
By showing to the patient when the correct flow rate is achieved
and sufficient volume has been inhaled, the maximal fine parti-
cle dose from a DPI and optimal deposition pattern of that fine
particle dose may be obtained. Recording of these data enables
the health-care professional to check compliance with the
instructions for inhaler use and adherence to the therapy.
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